Exelixis, Inc. (EXEL) News
Filter EXEL News Items
EXEL News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
EXEL News Highlights
- For EXEL, its 30 day story count is now at 20.
- Over the past 21 days, the trend for EXEL's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- DRUG, ILMN and JNJ are the most mentioned tickers in articles about EXEL.
Latest EXEL News From Around the Web
Below are the latest news stories about EXELIXIS INC that investors may wish to consider to help them evaluate EXEL as an investment opportunity.
GSK's Momelotinib Gets FDA Nod for Myelofibrosis-Related AnemiaGSK's Ojjaara (momelotinib) is the first and the only drug approved to treat myelofibrosis patients with anemia in the United States. |
4 Magnificent Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market DipWall Street has vacillated between bull and bear markets, with the growth-focused Nasdaq Composite (NASDAQINDEX: ^IXIC) being whipsawed more than any other major index. During the 2022 bear market, the innovation-fueled Nasdaq shed up to 38% of its value and ended the year lower by 33%. Through the first eight months and change of 2023, the Nasdaq Composite is higher by nearly 32%. |
2 Top Biotech Stocks Defying the Bear MarketLet's discuss why Exelixis and Axsome are solid picks for investors. Exelixis is an oncology specialist best known for its blockbuster cancer drug Cabometyx. For instance, Exelixis recently settled a patent litigation lawsuit with Teva Pharmaceuticals that will stop the generic drugmaker from launching Cabometyx's generics before 2031. |
Exelixis (EXEL) Gets Rights for Tumor Candidate From InsilicoExelixis (EXEL) enters into a license agreement with Insilico Medicine for ISM3091, a potentially best-in-class USP1 inhibitor. |
Exelixis and Insilico Medicine Enter into Exclusive Global License Agreement for ISM3091, a Potentially Best-in-Class USP1 InhibitorExelixis, Inc. (Nasdaq: EXEL) and Insilico Medicine ("Insilico") today announced that the companies have entered into an exclusive license agreement granting Exelixis global rights to develop and commercialize ISM3091, a potentially best-in-class small molecule inhibitor of USP1, which has emerged as a synthetic lethal target in the context of BRCA-mutated tumors. |
J&J (JNJ) Seeks Approval for Bladder Cancer Drug in EuropeJ&J's (JNJ) erdafitinib is already marketed as Balversa in the United States for FGFR-altered metastatic UC. Balversa is approved by the FDA under the accelerated pathway. |
Illumina (ILMN) Down 14.2% Since Last Earnings Report: Can It Rebound?Illumina (ILMN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. |
Exelixis, Inc. (NASDAQ:EXEL) Is Going Strong But Fundamentals Appear To Be Mixed : Is There A Clear Direction For The Stock?Exelixis (NASDAQ:EXEL) has had a great run on the share market with its stock up by a significant 15% over the last... |
J&J (JNJ) to End Pulmonary Hypertension Study on OpsumitThe decision to end the CTEPH study on J&J's (JNJ) Opsumit (macitentan) was made at the recommendation of the study's independent DMC, following a pre-planned interim analysis. |
AstraZeneca (AZN) Gets FDA CRL for Ultomiris in New IndicationAstraZeneca (AZN) said the CRL for Ultomiris for NMOSD indication does not raise any concerns about the efficacy and safety data from the study. |